BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: Results of a prospective randomized EORTC 20981 phase III intergroup study

Journal of Clinical Oncology

Volumn 28, Issue 13, 2010, Pages 2246-2252

  Van Oers, Marinus H J ^a   Tönnissen, Evelyn ^a   Van Glabbeke, Martine ^a   Giurgea, Livia ^a   Jansen, Joop H ^a   Klasa, Richard ^a   Marcus, Robert E ^a   Wolf, Max ^a   Kimby, Eva ^a   Vranovsky, Andrej ^a   Holte, Harald ^a   Hagenbeek, Anton ^a   Van Der Reijden, Bert A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; FOLLICULAR LYMPHOMA; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; TREATMENT RESPONSE; AUSTRALIA; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESISTANCE; EUROPE; GENE EXPRESSION REGULATION; GENETIC SCREENING; GENETICS; IMMUNOGLOBULIN HEAVY CHAIN GENE; METHODOLOGY; MORTALITY; MULTICENTER STUDY; NEW ZEALAND; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SOUTH AFRICA; STATISTICAL MODEL; TIME; TREATMENT FAILURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRALIA; CANADA; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EUROPE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, IMMUNOGLOBULIN HEAVY CHAIN; GENETIC TESTING; HUMANS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; LYMPHOMA, FOLLICULAR; NEW ZEALAND; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SOUTH AFRICA; TIME FACTORS; TREATMENT FAILURE; VINCRISTINE;

EID: 77952309861     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.0852     Document Type: Article

References (32)

1. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75-88, 1993
2. Johnson PW, Rohatiner AZ, Whelan JS, et al: Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol 13:140-147, 1995
3. Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064-3071, 2004 (Pubitemid 39517009)
4. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005 (Pubitemid 41742196)
5. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005 (Pubitemid 40223656)
6. Salles GAG, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood. 2008;112:4824-4831
7. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992, 2007
8. Buckstein R, Pennell N, Berinstein NL: What is remission in follicular lymphoma and what is its relevance? Best Practice & Research Clinical Haematology 18:27-56, 2005 (Pubitemid 40197864)
9. Mandigers CM, Meijerink JP, Mensink EJ, et al: Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma. Blood 98:940-944, 2001
10. Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103:4416-4423, 2004 (Pubitemid 38745964)
11. Rambaldi A, Carlotti E, Oldani E, et al: Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and longterm outcome in follicular non-Hodgkin lymphoma. Blood 105:3428-3433, 2005 (Pubitemid 40628182)
12. Gribben JG, Neuberg D, Barber M, et al: Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 83:3800-3807, 1994 (Pubitemid 24175572)
13. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al: The clinical significance of molecular response in indolent follicular lymphomas. Blood 91:2955-2960, 1998 (Pubitemid 28227546)
14. Haas R, Moos M, Karcher A, et al: Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol 12:1685-1692, 1994 (Pubitemid 24245005)
15. Price CG, Meerabux J, Murtagh S, et al: The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J Clin Oncol 9:1527-1532, 1991
16. Lambrechts AC, Hupkes PE, Dorssers LC, et al: Clinical significance of t(14; 18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission. J Clin Oncol 12:1541-1546, 1994
17. Ladetto M, Corradini P, Vallet S, et al: High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: A multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 100:1559-1565, 2002 (Pubitemid 34925127)
18. Moos M, Schulz R, Martin S, et al: The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma. Leukemia 12:1971-1976, 1998
19. Apostolidis J, Gupta RK, Grenzelias D, et al: High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow- up. J Clin Oncol 18:527-536, 2000 (Pubitemid 30078534)
20. Gribben JG, Neuberg D, Freedman AS, et al: Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81:3449-3457, 1993 (Pubitemid 23172933)
21. Hardingham JE, Kotasek D, Sage RE, et al: Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 13:1073-1079, 1995
22. Corradini P, Astolfi M, Cherasco C, et al: Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 89:724-731, 1997 (Pubitemid 27051709)
23. van Oers MH, Klasa R, Marcus RE, et al: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-3301, 2006 (Pubitemid 44794222)
24. Reference deleted
25. Paszkiewicz-Kozik E, Kulik J, Fabisiewicz A, et al: Presence of t(14;18) positive cells in blood and bone marrow does not predict outcome in follicular lymphoma. MedOncol 2008
26. Leonard BM, Hetu F, Busque L, et al: Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: Less than one log difference between bone marrow and peripheral blood sources. Blood 91:331-339, 1998 (Pubitemid 28018762)
27. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al: Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: Update of the MDACC series. Ann Oncol 11:137-140, 2001 (suppl 1)
28. Hirt C, Schuler F, Kiefer T, et al: Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: Clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. Br J Haematol 141:631-640, 2008 (Pubitemid 351688478)
29. Morschhauser F, Radford J, Van HA, et al: Phase III trial of consolidation therapy with yttrium- 90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-5164, 2008
30. Colombat P, Salles G, Brousse N, et al: Rituximab (anti-CD20 monoclonal antibody) as single firstline therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 97:101-106, 2001 (Pubitemid 32061248)
31. Schmitt C, Grundt A, Buchholtz C, et al: One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near? Leuk Res 30:1563-1568, 2006
32. van Oers MH: Rituximab maintenance therapy: A step forward in follicular lymphoma. Haematologica 92:826-833, 2007